{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-26-002608","form_type":"8-K","ticker":"PDSB","cik":"0001472091","company_name":"PDS Biotechnology Corp","filed_at":"2026-01-28T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.143200+00:00","generated_at":"2026-05-16T06:57:48.690439+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"PDS Biotech: NCI-led Phase 2 study of PDS01ADC shows median PFS 9.6 months in mCRPC","bullets":["Median PFS of 9.6 months (range 4.3-32.2) for PDS01ADC plus docetaxel in 3rd-line mCRPC patients.","Median PSA decline of 40%; 6 of 16 patients achieved >50% PSA decline.","Data presented at AACR special conference on prostate cancer (Boston, Jan 20-22, 2026).","Study by NCI/NIH evaluating PDS01ADC synergy with docetaxel in advanced prostate cancer."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-26-002608","json":"https://secwatch.observer/filing/0001140361-26-002608.json","markdown":"https://secwatch.observer/filing/0001140361-26-002608.md","text":"https://secwatch.observer/filing/0001140361-26-002608.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1472091/000114036126002608/0001140361-26-002608-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1472091/000114036126002608/ef20064069_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T06:57:48.690439+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}